On March 3, 2022 Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, reported that it will be presenting at two investor conferences in March 2022 (Press release, Citius Pharmaceuticals, MAR 3, 2022, View Source [SID1234609495]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Leonard Mazur, Executive Chairman of Citius, will discuss recent business developments and upcoming milestones. Registered participants will be able to view an on-demand corporate presentation through the conference websites and access an archived webcast of the presentations following each conference under "Events" in the Investors section of the Citius website.
34th Annual ROTH Conference
Date:
March 13-15, 2022
Location:
Ritz-Carlton, Laguna Niguel in Dana Point, California
Event website:
Conference registration
Interested parties may schedule 1-on-1 meetings with Citius management by registering through the event platform or contacting the Company’s investor relations team.
Maxim’s 2022 Virtual Growth Conference
Date:
March 28-30, 2022
Location:
Virtual
Event website:
Conference registration
Archived webcasts of the presentations will be accessible under "Events" in the Investors section of the Citius website